All Stories

  1. Is Aspirin Still Indispensable After PCI—Rethinking Dual Antiplatelet Therapy in Contemporary Practice
  2. Redefining Dual Antiplatelet Strategies After Acute Coronary Syndrome: Insights from Recent RCTs
  3. Impact of Coronary Function Testing on Symptoms and Quality of Life in Patients with Coronary Microvascular Dysfunction: Meta-Analysis of Randomised Controlled Trials
  4. An Updated Meta-Analysis of Randomized Controlled Trials Comparing Direct Oral Anticoagulants Against Warfarin for Left Ventricular Thrombus Resolution
  5. Response by Bulluck and Hausenloy to Letter Regarding Article, “Effect of Cangrelor on Infarct Size in ST-Segment–Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (the PITRI Trial)”
  6. Letter to the Editor Regarding “A Meta-Analysis of RCTs Comparing DOACs Against Warfarin for the Treatment of Left Ventricular Thrombus”
  7. Effect of Cangrelor on Infarct Size in ST-Segment–Elevation Myocardial Infarction Treated by Primary Percutaneous Coronary Intervention: A Randomized Controlled Trial (The PITRI Trial)
  8. Intravascular Imaging-Guided Versus Angiography-Guided Percutaneous Coronary Intervention on Medium-Term Outcomes: A Contemporary Meta-Analysis of Randomized Controlled Trials
  9. A Contemporary Review of Antiplatelet Therapies in Current Clinical Practice
  10. Defining Peri-Operative Myocardial Injury during Cardiac Surgery Using High-Sensitivity Troponin T
  11. Meta-Analysis Comparing Clinical Outcomes of Fractional-Flow-Reserve- and Angiography-Guided Multivessel Percutaneous Coronary Intervention
  12. Fractional Flow Reserve versus Angiography–Guided Management of Coronary Artery Disease: A Meta–Analysis of Contemporary Randomised Controlled Trials
  13. Meta-Analysis Comparing 10-Year Mortality Following Percutaneous Coronary Intervention or Coronary Artery Bypass Grafting in Left Main Stem or Multivessel Coronary Artery Disease
  14. Incidence and Clinical Predictors of Non-Obstructive Coronary Arteries in Patients With Suspected Non-ST Elevation Myocardial Infarction Undergoing Invasive Coronary Angiography
  15. Contemporary tools and devices for coronary calcium modification
  16. Prognostically relevant cardiac troponin elevations with percutaneous coronary interventions
  17. Combining Invasive Coronary Physiology With CMR for Long-Term Risk-Stratification in STEMI
  18. Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiov...
  19. Association between smoking status and outcomes in myocardial infarction patients undergoing percutaneous coronary intervention
  20. T and Small Protrusion (TAP) vs Double-Kissing Crush Technique: Insights From In Vitro Models
  21. Procedural myocardial injury, infarction and mortality in patients undergoing elective PCI: a pooled analysis of patient-level data
  22. Response to the letter to the editor regarding the study “Impact of time of onset of symptom of ST-segment elevation myocardial infarction on 1-year rehospitalization for heart failure and mortality” published in the American Heart Journal
  23. Effect of remote ischemic preConditioning on liver injury in patients undergoing liver resection: the ERIC-LIVER trial
  24. Cardioprotection for Acute MI in Light of the CONDI2/ERIC-PPCI Trial: New Targets Needed
  25. Redefining Adverse and Reverse Left Ventricular Remodeling by Cardiovascular Magnetic Resonance Following ST-Segment–Elevation Myocardial Infarction and Their Implications on Long-Term Prognosis
  26. The Lipid Paradox is present in ST-elevation but not in non-ST-elevation myocardial infarction patients: Insights from the Singapore Myocardial Infarction Registry
  27. Myocardial Edema, Myocyte Injury, and Disease Severity in Fabry Disease
  28. Periprocedural elevated myocardial biomarkers and clinical outcomes following elective percutaneous coronary intervention: a comprehensive dose-response meta-analysis of 44,972 patients from 24 prospective studies
  29. Periprocedural Cardiac Troponin and Mortality in Stable Patients Undergoing PCI
  30. Effect of remote ischaemic conditioning on clinical outcomes in patients with acute myocardial infarction (CONDI-2/ERIC-PPCI): a single-blind randomised controlled trial
  31. A Multicenter, Scan-Rescan, Human and Machine Learning CMR Study to Test Generalizability and Precision in Imaging Biomarker Analysis
  32. The Effect of Blood Composition on T1 Mapping
  33. Toward Improving Our Understanding of the Relationship Between IMR and MVO in STEMI Patients
  34. Independent Predictors of Cardiac Mortality and Hospitalization for Heart Failure in a Multi-Ethnic Asian ST-segment Elevation Myocardial Infarction Population Treated by Primary Percutaneous Coronary Intervention
  35. Optimized Treatment of ST-Elevation Myocardial Infarction
  36. Interrogation of the infarcted and salvaged myocardium using multi-parametric mapping cardiovascular magnetic resonance in reperfused ST-segment elevation myocardial infarction patients
  37. Feasibility to Perform T 2 * Mapping Postcontrast Administration in Reperfused STEMI Patients for the Detection of Intramyocardial Hemorrhage
  38. Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial
  39. Defining a ‘frequent admitter’ phenotype among patients with repeat heart failure admissions
  40. Platelet Inhibition to Target Reperfusion Injury (The PITRI trial): Rationale and Study Design
  41. Incidence and predictors of left ventricular thrombus by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction treated by primary percutaneous coronary intervention: a meta-analysis
  42. Coronary Microvascular Injury in Reperfused Acute Myocardial Infarction: A View From an Integrative Perspective
  43. Optimizing the Detection of Left Ventricular Thrombus Following Acute Myocardial Infarction in the Current Era
  44. Modulating NAD+ metabolism to prevent acute kidney injury
  45. Risk Stratification by Cardiovascular Magnetic Resonance After Reperfused ST-Segment Elevation Myocardial Infarction
  46. Impact of Cardioprotective Therapies on the Edema-Based Area at Risk by CMR in Reperfused STEMI
  47. Myocardial Edema and Prognosis in Amyloidosis
  48. Percutaneous coronary intervention of saphenous vein grafts: where do we stand?
  49. Cardiovascular Magnetic Resonance in Acute ST-Segment–Elevation Myocardial Infarction
  50. Letter by Bulluck and Hausenloy Regarding Article, “Dynamic Edematous Response of the Human Heart to Myocardial Infarction: Implications for Assessing Myocardial Area at Risk and Salvage”
  51. Cardiac Structural and Functional Consequences of Amyloid Deposition by Cardiac Magnetic Resonance and Echocardiography and Their Prognostic Roles
  52. Myocardial native T1 and extracellular volume with healthy ageing and gender
  53. Bivalirudin versus Heparin Monotherapy in Myocardial Infarction
  54. Fundamentals of bioresorbable stents
  55. Bioresorbable Scaffold Stability and Mechanical Properties
  56. Left Ventricular Hypertrophy Revisited
  57. Age and ejection fraction modify the impact of atrial fibrillation on acute heart failure outcomes
  58. Redefining viability by cardiovascular magnetic resonance in acute ST-segment elevation myocardial infarction
  59. Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
  60. Response by Andrews et al to Letter Regarding Article, “Electrical and Structural Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy Determined Using Noninvasive Electrocardiographic Imaging and Late Gadolinium Magnetic Resonance Imaging”
  61. Neutrophil gelatinase-associated lipocalin prior to cardiac surgery predicts acute kidney injury and mortality
  62. Quantification of both the area-at-risk and acute myocardial infarct size in ST-segment elevation myocardial infarction using T1-mapping
  63. ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Peri-operative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery
  64. Full left ventricular coverage is essential for the accurate quantification of the area-at-risk by T1 and T2 mapping
  65. Mapping Myocardial Salvage Index by Extracellular Volume Fraction
  66. Electrical and Structural Substrate of Arrhythmogenic Right Ventricular Cardiomyopathy Determined Using Noninvasive Electrocardiographic Imaging and Late Gadolinium Magnetic Resonance Imaging
  67. Magnetic Resonance in Transthyretin Cardiac Amyloidosis
  68. Quantifying the area-at-risk of myocardial infarction in-vivo using arterial spin labeling cardiac magnetic resonance
  69. Reply to “Circadian variation in acute myocardial infarction size: Likely involvement of the melatonin and suprachiasmatic nuclei”
  70. 024 Spectrum and significance of CMR findings in cardiac transthyretin amyloidosis
  71. 001 Multiparametric mapping to understand pathophysiology in cardiac amyloidosis
  72. Age and Surgical Complexity impact on Renoprotection by Remote Ischemic Preconditioning during Adult Cardiac Surgery: A Meta analysis
  73. Defining left ventricular remodeling following acute ST-segment elevation myocardial infarction using cardiovascular magnetic resonance
  74. Circadian variation in acute myocardial infarct size assessed by cardiovascular magnetic resonance in reperfused STEMI patients
  75. Myocardial Infarct Size by CMR in Clinical Cardioprotection Studies
  76. Invasive Assessment of the Coronary Microcirculation in Reperfused ST-Segment–Elevation Myocardial Infarction Patients
  77. Diagnostic performance of T 1 and T 2 mapping to detect intramyocardial hemorrhage in reperfused ST-segment elevation myocardial infarction (STEMI) patients
  78. Reply
  79. Bioresorbable stents: Current and upcoming bioresorbable technologies
  80. Gender Differences in Native Myocardial T1 in a Healthy Chinese Volunteer Cohort
  81. Impact of microvascular obstruction on semiautomated techniques for quantifying acute and chronic myocardial infarction by cardiovascular magnetic resonance
  82. Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy
  83. From basic mechanisms to clinical applications in heart protection, new players in cardiovascular diseases and cardiac theranostics: meeting report from the third international symposium on “New frontiers in cardiovascular research”
  84. Residual Myocardial Iron Following Intramyocardial Hemorrhage During the Convalescent Phase of Reperfused ST-Segment–Elevation Myocardial Infarction and Adverse Left Ventricular RemodelingCLINICAL PERSPECTIVE
  85. Index of Microvascular Resistance and Microvascular Obstruction in Patients With Acute Myocardial Infarction
  86. Cardiac Fabry Disease With Late Gadolinium Enhancement Is a Chronic Inflammatory Cardiomyopathy
  87. Optimization of coronary optical coherence tomography imaging using the attenuation-compensated technique: a validation study
  88. Automated Extracellular Volume Fraction Mapping Provides Insights Into the Pathophysiology of Left Ventricular Remodeling Post–Reperfused ST‐Elevation Myocardial Infarction
  89. ORAL AB II QUICK FIRE BASIC1393Validation of aortic in-vitro strain measurement by Magnetic Resonance Imaging with realistic abdominal aortic aneurism phantom1474A novel method of Segment Length Tracking providing regional strain measures from standard...
  90. Response to Letters Regarding Article, “Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis”
  91. Quantifying the Area at Risk in Reperfused ST-Segment–Elevation Myocardial Infarction Patients Using Hybrid Cardiac Positron Emission Tomography–Magnetic Resonance ImagingCLINICAL PERSPECTIVE
  92. Global longitudinal strain is associated with heart failure outcomes in hypertrophic cardiomyopathy
  93. Letter by Bulluck and Hausenloy Regarding Article, “Air Versus Oxygen in ST-Segment–Elevation Myocardial Infarction”
  94. High-sensitivity Troponin-T levels in reperfused STEMI patients: A comparison with CMR
  95. Chronic iron deposit and left ventricular remodeling in reperfused STEMI patients
  96. Left ventricular remodeling after reperfused acute myocardial infarction: insights from automated ECV mapping
  97. Automatic Measurement of the Myocardial Interstitium
  98. Clinical benefit of adenosine as an adjunct to reperfusion in ST-elevation myocardial infarction patients: An updated meta-analysis of randomized controlled trials
  99. Remote Ischemic Preconditioning: Would You Give Your Right Arm to Protect Your Kidneys?
  100. CMR findings in high endurance veteran athletes - a 247 subject study
  101. Diffuse myocardial fibrosis - a therapeutic target? Proof of regression at 1-year following aortic valve replacement: the RELIEF-AS study
  102. ECG, LVH and T1 changes in Fabry disease - implications for screening and understanding of the disease model
  103. Hematocrit, iron and HDL-cholesterol explain 90% of variation in native blood T1
  104. Native myocardial T1 and ECV with age and gender developing normal reference ranges - a 94 healthy volunteer study
  105. Reproducibility of native T1 mapping using ShMOLLI and MOLLI - implications for sample size calculation
  106. The Right ventricle and cardiac surgery - more resilient than thought: multiparametric quantification shows altered rather than reduced function
  107. Reducing myocardial infarct size: challenges and future opportunities
  108. Microvascular Obstruction: The Bane of Myocardial Reperfusion
  109. Obstrucción microvascular: el azote de la reperfusión miocárdica
  110. The Effect of Remote Ischemic Conditioning and Glyceryl Trinitrate on Perioperative Myocardial Injury in Cardiac Bypass Surgery Patients: Rationale and Design of the ERIC-GTN Study
  111. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac AmyloidosisCLINICAL PERSPECTIVE
  112. T1 mapping and T2 mapping at 3T for quantifying the area-at-risk in reperfused STEMI patients
  113. CardioPulse ArticlesEditors' network of the European Society of Cardiology National Cardiovascular Journals: scientific input from the National SocietiesHand grip strength predicts myocardial infarction and strokeEffect of remote ischaemic conditioning...
  114. Remote Ischemic Conditioning Reduces Myocardial Infarct Size in STEMI Patients Treated by Thrombolysis
  115. Mineralocorticoid Receptor Antagonist Pretreatment to MINIMISE Reperfusion Injury After ST-Elevation Myocardial Infarction (The MINIMISE STEMI Trial): Rationale and Study Design
  116. Ischaemic conditioning: are we there yet?
  117. 29 Synthetic ECV – simplifying ECV quantification by deriving haematocrit from T1 blood
  118. Safety of short-term dual antiplatelet therapy after drug-eluting stents: An updated meta-analysis with direct and adjusted indirect comparison of randomized control trials
  119. An instantaneous ECV with no blood sampling: using native blood T1 for hematocrit is as good as standard ECV
  120. Clinical application of MOLLI T1* for extracellular volume calculation in healthy volunteers and aortic stenosis
  121. Hybrid PET/MR metabolic imaging of the reperfused infarct - new biology, future directions
  122. Incidence of left ventricular thrombi in reperfused STEMI patients detected by contrast-enhanced CMR
  123. LGE-PSIR is an independent predictor of mortality in cardiac amyloidosis: a 250 patient prospective study
  124. Myocardial T1 Mapping
  125. Myocardial iron quantification using T2* and native T1mapping - a 250 patient study
  126. Performance of automated ECV maps versus conventionally calculated ECV
  127. Precision and reproducibility of blood T1 estimation: implications of T1 star on ECV calculation
  128. Quantification of the area-at-risk by T1 and T2 mapping CMR at 3T
  129. A simple technique to measure TAPSE and MAPSE on CMR and normal values
  130. AL and ATTR cardiac amyloid are different: native T1 mapping and ECV detect different biology
  131. Benefits and Harms of Extending the Duration of Dual Antiplatelet Therapy after Percutaneous Coronary Intervention with Drug-Eluting Stents: A Meta-Analysis
  132. CMR detects a reduction in infarct size and myocardial edema when primary PCI is augmented by Remote Ischemic Conditioning. A randomized trial
  133. 045 PRIMARY PERCUTANEOUS CORONARY INTERVENTION FOR ST ELEVATION MYOCARDIAL INFARCTION: DOES DIRECT STENTING IMPACT ON MORTALITY?
  134. The aetiology of symptomatic gallstones quantification of the effects of obesity, alcohol and serum lipids on risk. Epidemiological and biomarker data from a UK prospective cohort study (EPIC-Norfolk)
  135. S1238 Serum Lipids and the Risk of Developing Symptomatic Gallstones: A UK Prospective Cohort Study
  136. OC-030 Serum lipids and the risk of developing symptomatic gallstones: a UK prospective cohort study
  137. 14 Body Mass Index and the Risk of Symptomatic Gallstones - A Prospective Cohort Study in a UK Population
  138. 15 Alcohol Intake and Development of Symptomatic Gallstones: An Inverse Association - A UK Prospective Cohort Study